2025-11-17T11:18:11-06:00 2024-12-31 410746749 CLIFTONLARSONALLEN LLP 227 WEST TRADE STREET SUITE 800 CHARLOTTE NC 28202 990 2024-01-01 010648145 ORTHOCAROLINA RESEARCH INSTITUTE INC ORTH 7043232260 2001 VAIL AVENUE SUITE 300 CHARLOTTE NC 28207 CHRISTI CADD EXECUTIVE DIRECTOR 7043232260 2025-11-14 1 1 KATHRINE A WARLICK P02065266 7049985200 2025-11-14 2024 2025-03-06 01:10:19Z CHRISTI CADD 2001 VAIL AVENUE SUITE 300 CHARLOTTE NC 28207 2643097 0 X WWW.ORTHOCAROLINARESEARCH.ORG X 2002 NC TO PROMOTE, DEVELOP AND CONDUCT STATE OF THE ART SCIENTIFIC RESEARCH AND EDUCATIONAL PROGRAMS FOR THE ADVANCEMENT OF ORTHOPEDIC CARE. OCRI WORKS BOTH INDEPENDENTLY AS WELL AS IN COLLABORATION WITH UNIVERSITIES, HOSPITALS, PHARMACEUTICAL AND DEVICE COMPANIES AND OTHER ACADEMIC AND RESEARCH ORGANIZATIONS TO FURTHER PROMOTE THE MISSION. 12 12 0 12 0 0 989188 2030884 507419 347405 350471 264808 0 0 1847078 2643097 0 0 0 0 0 0 52500 0 124814 2250260 2078142 2302760 2078142 -455682 564955 3695403 4084479 667059 485673 3028344 3598806 THE ORTHOCAROLINA RESEARCH INSTITUTE (OCRI) IS AN INDEPENDENT, NON-PROFIT 501(C)3 THAT EXISTS TO FACILITATE RELEVANT ORTHOPEDIC RESEARCH WHICH ADVANCES ORTHOPEDIC TREATMENTS, IMPROVES QUALITY OF LIFE FOR PATIENTS, AND EDUCATES THE MEDICAL COMMUNITY. 0 0 1327706 347405 THE INSTITUTE'S MISSION AND PRIORITIES ARE CENTRALLY FOCUSED ON (1) IMPROVED ORTHOPEDIC PATIENT CARE AND (2) HIGH QUALITY EVIDENCE-BASED RESEARCH TO DEVELOP NEW AND INNOVATIVE ORTHOPEDIC DEVICES AND TECHNOLOGIES WHOSE GOAL IS TO ANSWER CLINICAL QUESTIONS FOR IMPROVED OUTCOMES. THE INSTITUTE LEADS ONGOING FDA-REGULATED CLINICAL TRIALS AND INVESTIGATOR-INITIATED SCIENTIFIC ACADEMIC STUDIES. RESEARCH IS DISSEMINATED THROUGH PEER REVIEWED JOURNAL PUBLICATIONS WITH GREATER THAN 85 PUBLICATIONS ANNUALLY. 88957 THE INSTITUTE'S MISSION IS FOCUSED ON ADVANCING BOTH RESEARCH AND EDUCATION IN ORTHOPEDICS. THE ORTHOCAROLINA RESEARCH INSTITUTE HOSTS AN EDUCATIONAL CME (CONTINUING MEDICAL EDUCATION) SYMPOSIUM, KNOWN AS OSCAR MILLER DAY, FOR 350-400 ORTHOPEDIC PROVIDERS AND ALLIED HEALTH CARE PROFESSIONALS EACH YEAR. THIS SYMPOSIUM IS OVER 40 YEARS OLD AND IS MARKETED TO THE SOUTHEASTERN U.S. TOPICS ARE ROTATED ANNUALLY. 5167 ARMS FOR ALL IS A PROGRAM UNDER OCRI THAT COVERS THE GAP EXPENSE BETWEEN WHAT INSURANCE WILL COVER AND WHAT IS THE BEST PROSTHETIC FOR IMPROVED QUALITY OF LIFE FOR PATIENTS WHO HAVE LOST A LIMB. 1421830 1 1 0 0 0 0 0 1 0 0 1 1 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 12 12 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 SC X CHRISTI CADD 7043232134 2001 VAIL AVENUE SUITE 300 CHARLOTTE NC 28207 CLENN GASTON MD CHAIRMAN 2.00 X X 0 0 0 PATRICK M CONNOR BOARD DIRECTOR 0.25 X 0 0 0 BRUCE DARDEN MD BOARD DIRECTOR 0.10 X 0 0 0 CHARLES EAST III BOARD DIRECTOR 0.25 X 0 0 0 JOHN L FRALEY JR BOARD DIRECTOR 0.10 X 0 0 0 WILLIAM GRIFFIN MD BOARD DIRECTOR 0.10 X 0 0 0 FRED R JONES BOARD DIRECTOR 0.50 X 0 0 0 TOM SMITH BOARD DIRECTOR 0.50 X 0 0 0 RICHARD E THIGPEN BOARD DIRECTOR 0.25 X 0 0 0 VELVA WOOLEN BOARD DIRECTOR 0.25 X 0 0 0 BRIAN CURTIN MD BOARD DIRECTOR 1.50 X 0 0 0 NANCY MCNELLIS BOARD DIRECTOR 0.50 X 0 0 0 CHRISTI CADD EXECUTIVE DIRECTOR 50.00 X 157385 0 24081 157385 0 24081 1 0 1 0 0 2030884 2030884 RESEARCH INCOME 541700 347405 347405 347405 264808 264808 2643097 347405 0 264808 28607 28607 478 478 36762 31842 4920 55113 55113 48837 48837 4858 1216 3642 20937 20937 PAYROLL REIMBURSEMENT 1636651 1170310 358966 107375 STUDY EXPENSES 122267 122267 OSCAR MILLER DAY EXPENS 88957 88957 ARMS FOR ALL 5167 5167 29508 2071 9998 17439 2078142 1421830 531498 124814 332268 459672 722500 382671 218448 33891 31086 63378 63378 0 0 2894717 2434231 51856 218542 3695403 4084479 618110 279293 13093 2927 35856 203453 667059 485673 X 1828508 2266288 1199836 1332518 3028344 3598806 3695403 4084479 564955 5507 0 X X 0 1 X 1 0 X 1258438 2015726 945893 989188 2030884 7240129 748260 889967 633547 507419 347405 3126598 2006698 2905693 1579440 1496607 2378289 10366727 509022 541573 233001 174171 254382 1712149 352082 235526 97529 61970 747107 861104 777099 233001 271700 316352 2459256 7907471 5 350471 264808 615284 5 350471 264808 615284 5000 5000 2006703 2910693 1579440 1847078 2643097 10987011 0.71970 0.72920 0.05600 0.03040 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 16000 16000 X X 16000 0 13878 13878 0 49500 49500 0 0 BENEFICIAL INTEREST IN POOLED FUNDS 2434231 F 2434231 WORK OF ART 16000 RIGHT OF USE ASSET 202542 218542 CURRENT LEASE LIABILITY 37543 LEASE LIABILITY, NET OF CURRENT PORTION 165910 203453 X 2383796 5507 5507 2378289 264808 264808 2643097 2078142 0 2078142 0 2078142 PART III, LINE 4: A GRATEFUL PATIENT GIFTED A PIECE OF GLASS ART WITH A $16,000 APPRAISED VALUE IN HONOR OF DR. WALTER BEAVER TO THE ORTHOCAROLINA RESEARCH INSTITUTE. IT IS DISPLAYED IN THE PATIENT WAITING ROOM. IT HAS NO RELEVANCE TO THE ORGANIZATION'S MISSION. PART X, LINE 2: THE INSTITUTE ADOPTED FASB GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE GUIDANCE CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN AN ENTITY'S FINANCIAL STATEMENTS BY PRESCRIBING A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN. THE INSTITUTE'S POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE INSTITUTE, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION TAKEN BY MANAGEMENT WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT BELIEVES THERE ARE NO SUCH POSITIONS AS OF DECEMBER 31, 2024 AND 2023 AND, ACCORDINGLY, NO LIABILITY HAS BEEN ACCRUED. PART XI, LINE 4B - OTHER ADJUSTMENTS: CHANGE IN BENEFICIAL INTEREST IN POOLED FUNDS 264,808. X X 0 0 0 0 0 0 0 1 0 CHRISTI CADD EXECUTIVE DIRECTOR 144811 0 12574 0 0 0 8464 0 15617 0 181466 0 0 0 PART I, LINE 3 THE ORTHOCAROLINA HR DEPARTMENT, A RELATED ORGANIZAT6ION, PERFORMS A SALARY SURVEY AND RE-EVALUATION PERIODICALLY OF POSITIONS. THEY SET THE COMPENSATION FOR ALL EMPLOYEES AND ALL POSITIONS. A MARKET ANALYSIS WAS PERFORMED IN 2023 AND A 15% INCREASE WAS ADDED TO THE EXECUTIVE DIRECTOR'S SALARY AS AN ADJUSTMENT BASED ON CURRENT MARKET. SALARY IS STILL LOWER THAN MARKET STANDARD BUT NO FUTURE ADJUSTMENTS ARE PLANNED AT THIS TIME. PART I, LINE 7 A MORE DEFINED BONUS STRUCTURE WAS INTRODUCED IN 2023 FOR THE EXECUTIVE DIRECTOR. IT WAS NOT SOLELY CONTINGENT ON NET REVENUE BUT WAS BASED ON RAISING MONEY FOR THE ORGANIZATION AND GETTING ORGANIZATIONAL INITIATIVES OFF THE GROUND. FORM 990, PART VI, SECTION A, LINE 1A THE FINANCE/AUDIT COMMITTEE HAS AUTHORITY TO HIRE THE AUDITORS. THE COMMITTEE REVIEWS ALL OTHER FINANCIAL FUNCTIONS MAKING RECOMMENDATIONS TO THE BOARD FOR APPROVAL. FORM 990, PART VI, SECTION A, LINE 3 THE EXECUTIVE COMMITTEE IS COMPRISED OF THE PRESIDENT, VICE-PRESESIDENT, FUNDRAISING COMMITTEE CHAIR AND GOVERANCE COMMITTE CHAIR AS VOTED AT THE DECEMBER 2024 BOARD MEETING. ALL ARE VOTING MEMBERS OF THE GOVERNING BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE 990 WILL BE REVIEWED BY THE EXECUTIVE DIRECTOR, FOLLOWED BY A REVIEW AND RECOMMENDATION BY THE OCRI FINANCE AND AUDIT COMMITTEE. THE FINAL COPY WITH THE FINANCE AND AUDIT COMMITTEES RECOMMENDATION WILL BE CIRCULATED VIA EMAIL TO THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C THE EXECUTIVE DIRECTOR, BOARD MEMBERS AND KEY EMPLOYEES CERTIFY ANNUALLY THAT THEY HAVE READ THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND HAVE DISCLOSED ANY RELATIONSHIPS WITH ANY OF THE ORGANIZATION'S CONTRACTING PARTIES ON THE ORGANIZATIONS CONFLICT OF INTEREST FORM. THE EXECUTIVE DIRECTOR REVIEWS THE CERTIFIED FORMS AND COMPARES IT TO THE PRIOR YEAR'S DISCLOSURES. QUESTIONABLE RELATIONSHIPS ARE NOTED AND BROUGHT TO THE ATTENTION OF THE APPROPRIATE GOVERNANCE GROUP. THE EXECUTIVE DIRECTOR DISCLOSES TO THE FINANCE AND AUDIT COMMITTEE ANY ITEMS THAT AFFECT BUSINESS COMPLIANCE DURING THE NEXT SCHEDULED MEETING AND DISCLOSES CONFLICTS RELATED TO THE RESEARCH TO THE RESEARCH ADVISORY COMMITTEE. APPROPRIATE STEPS ARE TAKEN TO ELIMINATE THE CONFLICT PER COMMITTEE GUIDANCE. FORM 990, PART VI, SECTION B, LINE 15 HUMAN RESOURCES DETERMINES INITIAL COMPENSATION BASED ON MARKET ANALYSIS FOR EXECUTIVE DIRECTOR AND OTHER KEY POSITIONS. THE HUMAN RESOURCE DEPARTMENT ESTABLISHES MIN, MID AND MAX SALARY RANGE FOR ALL POSITIONS IN OCRI BASED ON MARKET ANALYSIS. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2023. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY AND FINANCIALS STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART XII, LINE 2C: THE PROCESS FOR OVERSIGHT AND SELECTION OF AN INDEPENDENT ACCOUNTANT HAS NOT CHANGED FROM THE PRIOR YEAR.